Cullinan Management (CGEM)
NASDAQ:CGEM
Want to see CGEM full AI Analyst Report?
Top Page
Cullinan Management
(NASDAQ:CGEM)
Select Model
Select Model
Rating:51Neutral
Price Target:
$15.00
▼(-0.40% Downside)
Action:ReiteratedDate:03/24/26
The score is primarily constrained by weak financial performance (minimal revenue, widening losses, and significant ongoing cash burn). Technicals add only modest support due to mixed momentum and a near-term pullback, while valuation is limited by a negative P/E. Offsetting these risks, corporate events are constructive, with a well-funded runway and multiple 2026 clinical/regulatory catalysts that could improve the outlook if results are favorable.
Positive Factors
Strong cash runway
A reported cash/investment position of roughly $439M and runway into 2029 provides multi-year funding to advance clinical programs and regulatory filings. This durable liquidity reduces near-term financing pressure and supports execution of 2026 catalysts without immediate capital raises.
Negative Factors
Minimal recurring revenue
The company remains development-stage with little recurring revenue, meaning long-term business viability depends on future approvals or licensing converting pipeline assets into sales. Until commercialization, dependence on milestone/licensing receipts and financings is persistent and structural.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash runway
A reported cash/investment position of roughly $439M and runway into 2029 provides multi-year funding to advance clinical programs and regulatory filings. This durable liquidity reduces near-term financing pressure and supports execution of 2026 catalysts without immediate capital raises.
Read all positive factors
Cullinan Management (CGEM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$801.94M
Dividend YieldN/A
Average Volume (3M)795.18K
Price to Earnings (P/E)―
Beta (1Y)0.70
Revenue GrowthN/A
EPS Growth-18.75%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.77
Shares Outstanding61,451,380
10 Day Avg. Volume731,245
30 Day Avg. Volume795,184
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.48
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.47K
Enterprise Value/Ebitda-2.86
Forecast
1Y Price Target
$31.67Price Target Upside110.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.91
Revenue Forecast (FY)$29.10M
Cullinan Management Business Overview & Revenue Model
Company Description
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The c...
How the Company Makes Money
Cullinan Oncology generates revenue primarily through the development, commercialization, and partnership of its oncology drug candidates. The company collaborates with research organizations, licensing its proprietary technologies and intellectua...
Cullinan Management Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 18.94M |
| Gross Profit | -311.00K | -306.00K | -310.00K | 0.00 | 18.94M |
| EBITDA | -241.65M | -167.15M | -190.34M | -132.04M | -67.90M |
| Net Income | -219.88M | -167.38M | -153.16M | 111.21M | -65.57M |
Balance Sheet | |||||
| Total Assets | 448.37M | 621.82M | 484.18M | 561.12M | 437.19M |
| Cash, Cash Equivalents and Short-Term Investments | 377.90M | 398.98M | 467.07M | 467.29M | 290.47M |
| Total Debt | 2.68M | 2.15M | 3.59M | 5.19M | 0.00 |
| Total Liabilities | 39.64M | 31.50M | 30.29M | 26.09M | 11.81M |
| Stockholders Equity | 408.73M | 590.33M | 453.70M | 535.03M | 424.97M |
Cash Flow | |||||
| Free Cash Flow | -175.80M | -145.30M | -134.48M | -127.80M | -44.02M |
| Operating Cash Flow | -175.75M | -145.30M | -134.28M | -126.66M | -43.43M |
| Investing Cash Flow | 179.99M | -136.31M | 35.81M | 248.97M | -333.77M |
| Financing Cash Flow | 1.09M | 266.19M | 40.75M | -25.93M | 268.78M |
Cullinan Management Technical Analysis
Positive
15.06
Price Trends
13.95
Positive
12.53
Positive
9.99
Positive
Market Momentum
0.30
Negative
57.80
Neutral
62.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEM, the sentiment is Positive. The current price of 15.06 is above the 20-day moving average (MA) of 14.18, above the 50-day MA of 13.95, and above the 200-day MA of 9.99, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 57.80 is Neutral, neither overbought nor oversold. The STOCH value of 62.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGEM.
Cullinan Management Risk Analysis
Cullinan Management disclosed 79 risk factors in its most recent earnings report. Cullinan Management reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cullinan Management Peers Comparison
UnderperformOutperform
Sector (51)
CGEM
Cullinan Management
13.05
4.53
53.17%
RNTX
Rein Therapeutics
1.36
-0.28
-17.38%
NEUP
Neuphoria Therapeutics
5.27
0.27
5.40%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.